UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2002

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM __________ TO _________

COMMISSION FILE NUMBER: 000-25132

MYMETICS CORPORATION
(Exact name of Registrant as specified in its charter)

           DELAWARE                                         25-1741849
(State or other jurisdiction of                          (I.R.S. Employer
incorporation or organization)                           Identification No.)

                         706 GIDDINGS AVENUE, SUITE 1C
                        ANNAPOLIS, MARYLAND 21401-1472
                   (Address of principal executive offices)

410-990-9596
(Registrant's telephone number, including area code)

50-52 AVENUE CHANOINE CARTELLIER
69230 SAINT-GENIS LAVAL, FRANCE
(Former address, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No


Indicate the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date:

Class                               Outstanding at May 6, 2002
-----                               --------------------------

Common Stock, $0.01                      49,271,962(1)
par value

(1) These shares consist of (i) 32,878,646 shares of common stock which are currently issued and outstanding and (ii) 16,393,316 shares of common stock which are issuable upon the conversion of 15,372 outstanding exchangeable preferred shares of the Corporation's subsidiary 6543 Luxembourg S.A., which are presently convertible.

FORWARD-LOOKING STATEMENTS

Statements in this report, to the extent that they are not based on historical events, constitute forward-looking statements. Forward-looking statements include, without limitation, statements regarding the outlook for future operations, forecasts of future costs and expenditures, the evaluation of market conditions, the outcome of legal proceedings, the adequacy of reserves or other business plans. Investors are cautioned that forward-looking statements are subject to an inherent risk that actual results may vary materially from those described herein. Factors that may result in such variance, in addition to those accompanying the forward-looking statements, include changes in interest rates, prices and other economic conditions; actions by competitors; natural phenomena; actions by government authorities; uncertainties associated with legal proceedings; technological development; future decisions by management in response to changing conditions; and misjudgments in the course of preparing forward-looking statements.


PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MYMETICS CORPORATION & SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

(IN THOUSANDS OF EUROS)

                                                            MARCH 31, 2002                DECEMBER 31, 2001
                                                            --------------                -----------------

        ASSETS

Current Assets
        Cash                                             (E)               674       (E)                     888
        Short term investments                                              76                               354
        Receivables                                                         89                                49
        Prepaid expenses                                                    52                                31
                                                         ----------------------      ----------------------------
                       Total current assets                                891                             1,322

Patents and Other                                                          215                               161

Goodwill                                                                   209                               209
                                                         ----------------------      ----------------------------
                                                         (E)             1,315       (E)                   1,692
                                                         ======================      ============================

        LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
        Accounts payable                                 (E)               588       (E)                     436
        Taxes and social costs payable                                      85                                83
        Note payable, related party                                        232                               228
        Other                                                                6                                10
                                                         ----------------------      ----------------------------
                       Total current liabilities                           911                               757

Payable to shareholders                                                    242                               242

Shareholders' Equity
        Common stock                                                       562                               562
        Paid-in capital                                                 17,430                            17,422
        Deficit accumulated during the development stage               (17,947)                          (17,391)
        Cumulative translation adjustment                                  117                               100
                                                         ----------------------      ----------------------------
                                                                           162                               693

                                                         ----------------------      ----------------------------
                                                         (E)             1,315       (E)                   1,692
                                                         ======================      ============================

The accompanying notes are an integral part of these financial statements.


MYMETICS CORPORATION & SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)

(IN THOUSANDS OF EUROS, EXCEPT FOR PER SHARE AMOUNTS)

                                                    FOR THREE                   FOR THREE                TOTAL ACCUMULATED
                                                  MONTHS ENDED                 MONTHS ENDED                 DURING THE
                                                 MARCH 31, 2002               MARCH 31, 2001             DEVELOPMENT STAGE
                                                 --------------               --------------             -----------------

Revenue
       Sales                                  (E)                 -        (E)                 -    (E)                     224
       Interest                                                   5                            3                             31
                                              ----------------------      -----------------------   ----------------------------
                                                                  5                            3                            255
                                              ----------------------      -----------------------   ----------------------------

Expenses
       Research and development                                 232                          114                          1,076
       General and administrative                               250                          127                          1,865
       Bank fee                                                   -                        3,054                         14,869
       Interest                                                   9                           19                            104
       Amortization                                               1                           41                            195
       Other                                                     69                            -                             87
                                              ----------------------      -----------------------   ----------------------------
                                                                561                        3,355                         18,196
                                              ----------------------      -----------------------   ----------------------------

Loss before income tax provision                               (556)                      (3,352)                       (17,941)

Income tax provision                                              -                            -                              6
                                              ----------------------      -----------------------   ----------------------------
Net loss                                                       (556)                      (3,352)                       (17,947)

Other comprehensive income
       Foreign currency translation                              17                            -                            117
         Adjustment
                                              -----------------------     -----------------------    ---------------------------
Comprehensive loss                            (E)              (539)      (E)             (3,352)    (E)                (17,830)
                                              =======================     =======================    ===========================



Basic and diluted loss per share              (E)             (0.01)      (E)              (0.10)    (E)                  (0.52)
                                              =======================     =======================    ===========================

The accompanying notes are an integral part of these financial statements.


MYMETICS CORPORATION & SUBSIDIARIES
(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

(IN THOUSANDS OF EUROS)

                                                                  FOR THREE              FOR THREE            TOTAL
                                                                                                           ACCUMULATED
                                                                 MONTHS ENDED           MONTHS ENDED        DURING THE
                                                                MARCH 31, 2002         MARCH 31, 2001   DEVELOPMENT STAGE
                                                                --------------         --------------   -----------------



Cash flow from operating activities
Net Loss                                                      (E)          (556)     (E)  (3,352)         (E)  (17,947)
Adjustments to reconcile net loss to
        net cash used in operating
           activities
                  Amortization                                                1               41                   195
                  Fees paid in warrants                                       -            3,054                14,063
                  Fee paid in common stock                                    -                -                   806
                  Changes in current assets and
                  liabilities, net of effects from
                  reverse purchase
                     Decrease (increase) in receivables                     (40)              12                   (51)
                     Increase (decrease) in
                     accounts payable                                       152              153                   290
                     Increase (decrease) in taxes and
                     social costs payable                                     2              (24)                   85
                     Other                                                  (25)              (1)                    2

                                                              -------------------    -------------------  ---------------
                                                                           (466)            (117)               (2,557)
                                                              -------------------    -------------------  ---------------

Cash flows from investing activities
        Patents and other                                                   (55)             (34)                 (290)
        Short-term investments                                              278              (82)                  (76)
        Cash acquired in reverse purchase                                     -               13                    13

                                                              -------------------    -------------------  ---------------
                                                                            223             (103)                 (353)
                                                              -------------------    -------------------  ---------------


Cash flows from financing activities
        Proceeds from issuance of common stock                                8                -                 2,851
        Borrowing from shareholders                                           -                -                   242
        Increase in note payable and other
           short-term advances                                                4              200                   504
        Loan fees                                                             -                -                  (130)
                                                                    -----------    -------------       ---------------
                                                                             12              200                 3,467

Effect of foreign exchange rate on cash                                      17                -                   117

                                                                    -----------    -------------       ---------------
Net change in cash                                                         (214)             (20)                  674

Cash, beginning of period                                                   888              185                     -

                                                                    -----------    -------------       ---------------
Cash, end of period                                                 (E)     674    (E)       165       (E)         674
                                                                    ===========    =============       ===============

The accompanying notes are an integral part of these financial statements.


MYMETICS CORPORATION & SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2002
(UNAUDITED)

NOTE 1. BASIS OF PRESENTATION

The interim period consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2001. The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three month period ended March 31, 2002, were of a normal, recurring nature. The amounts presented for the three month period ended March 31, 2002, are not necessarily indicative of the results of operations for a full year.

NOTE 2. (LOSS) EARNINGS PER SHARE

Basic (loss) earnings per share is computed by dividing (loss) income available to common shareholders by the weighted average number of common shares outstanding in the period.

Diluted (loss) earnings per share takes into consideration common shares outstanding (computed under basic (loss) earnings per share) and potentially dilutive common shares. The weighted average number of shares outstanding for the purposes of calculating basic and diluted earnings per share was 49,262,518 for the three months ended March 31, 2002 and 33,585,685 for the three months ended March 31, 2001 and 34,409,516 for the development stage period.

The potentially dilutive common shares did not have an impact on diluted earnings per share for the three months ended March 31, 2002 and 2001, respectively, because the warrants and stock options to purchase common stock were anti-dilutive.

NOTE 3. REPORTING CURRENCY

Consistent with the location of its activities, beginning January 1, 1999, the Corporation adopted the euro (E) as its corporate currency. Accordingly, the Company prepared its 2001 and 2000 financial statements in euros.


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the results of operations and financial condition of Mymetics Corporation (the "Corporation") for the three months ended March 31, 2002 should be read in conjunction with the Corporation's consolidated financial statements and related notes included elsewhere herein.

RESULTS OF OPERATIONS - THREE MONTHS ENDED MARCH 31, 2002 COMPARED TO THREE MONTHS ENDED MARCH 31, 2001

Revenue for the three months ended March 31, 2002 was (E)5,000 compared to (E)3,000 for the three months ended March 31, 2001.

Expenses decreased to (E)561,000 for the three months ended March 31, 2002 from (E)3,355,000 for the three months ended March 31, 2001. Research and development expenses increased to (E)232,000 in the current period from (E)114,000 in the comparative period of 2001 as a result of an increase in research activities. General and administrative expenses increased to (E)250,000 in the three months ended March 31, 2002 from (E)127,000 in the comparative period of 2001 primarily as a result of the Company's business and structure, an expansion of the management team of the Corporation to include a Chief Executive Officer, a Chief Scientific Officer and a Vice-President of Development, and the additional use of consultants. Bank fees were nil for the three months ended March 31, 2002 compared to (E)3,054,000 over the comparative period in 2001, primarily as a result of a reverse purchase transaction that occured last year.

The Corporation reported a net loss of (E)556,000, or (E)0.01 per share, for the three months ended March 31, 2002, compared to (E)3,352,000, or (E)0.10, for the three months ended March 31, 2001.

LIQUIDITY AND CAPITAL RESOURCES

The Corporation had cash (E)674,000 at March 31, 2002, compared to (E)888,000 at December 31, 2001.

Net cash used by operating activities was (E)466,000 for the three months ended March 31, 2002, compared to (E)117,000 for the three months ended March 31, 2001. An increase in accounts payable provided cash of (E)152,000 for the three months ended March 31, 2002 compared to (E)153,000 for the three months ended March 31, 2001.

Investing activities provided cash of (E)223,000 for the three months ended March 31, 2002 compared to using cash of (E)103,000 for the same period last year. Short term investment provided cash of (E)278,000 for the three months ended March 31, 2002 compared to using cash of (E)82,000 for the three months ended March 31, 2001.

Financing activities provided cash of (E)12,000 for the three months ended March 31, 2002 compared to (E)200,000 in the same period last year. The revolving term facility is in the principal amount of up to (E)1.3 million and matures on August 31, 2002. At March 31, 2002, Mymetics had borrowed an aggregate of (E)232,000 pursuant to this revolving term facility.

The Corporation expects that it will require substantial additional capital to continue its research and development, clinical studies and regulatory activities necessary to bring its potential products to market and to establish production, marketing and sales capabilities. The Corporation will seek to raise the required capital from lenders and/or equity or debt issuances. However, there can be no


assurance that the Corporation will be able to raise additional capital on terms satisfactory to the Corporation, or at all, to finance its operations. In the event that the Corporation is not able to obtain such additional capital, it would be required to restrict or even halt its operations.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Corporation is exposed to market risk from changes in interest rates which could affect its financial condition and results of operations. The Corporation has not entered into derivative contracts for its own account to hedge against such risk.

INTEREST RATE RISK

Fluctuations in interest rates may affect the fair value of financial instruments sensitive to interest rates. An increase in interest rates may decrease the fair value and a decrease in interest rates may increase the fair value of such financial instruments. The Corporation has debt obligations which are sensitive to interest rate fluctuations. The following tables provide information about the Corporation's exposure to interest rate fluctuations for the carrying amount of such debt obligations as of March 31, 2002 and 2001 and expected cash flows from these debt obligations:

                                                       AS AT MARCH 31, 2002
                                                          (IN THOUSANDS)

                                                      EXPECTED FUTURE CASH FLOW
                                                      -------------------------
                                                      YEAR ENDING DECEMBER 31,
                  CARRYING        FAIR                ------------------------
                    VALUE        VALUE      2002        2003       2004       2005       2006        THEREAFTER
                    -----        -----      ----        ----       ----       ----       ----        ----------

----------------------------------------------------------------------------------------------------------------

Debt obligations    (E)232       (E)232    (E)232      (E) -      (E) -      (E) -       (E) -           (E) -
----------------------------------------------------------------------------------------------------------------

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.


ITEM 5. OTHER INFORMATION

BOARD OF DIRECTORS

On February 7, 2002, the board of directors of the Corporation (the "Board of Directors"), in accordance with Section 4.03 of the Corporation's bylaws, voted to expand the Board of Directors from 5 directors to 6 directors. Pursuant to Section 4.04 of the Corporation's bylaws, the Board of Directors elected Dr. Peter P. McCann to fill the newly created vacancy. Dr. McCann is designated a Class 3 Director and will serve until the next selection of the Class 3 Directors at the Corporation's annual meeting in 2003. Mr. McCann was also appointed as President and Chief Executive Officer of the Corporation.

The Board of Directors also appointed Dr. Pierre Francois Serres, former President and Chief Executive Officer, as the Corporation's Chief Scientific Officer. As Chief Scientific Officer, Dr. Serres will be responsible for developing and implementing the Corporation's scientific strategy, recruiting, managing and supervising the Corporation's scientific staff, and collaborating with potential corporate and academic partners.

The changes described above were all effective as of February 7, 2002.

EMPLOYMENT AGREEMENTS

On March 18, 2002, the Corporation entered into an employment agreement with its President and Chief Executive Officer, Dr. Peter P. McCann, pursuant to which he receives an annual salary of one hundred seventy thousand U.S. Dollars ($170,000) and normal benefits. In addition, Dr. McCann may participate in the Corporation's 2001 Stock Option Plan, as well as receive discretionary bonuses as approved by the Board of Directors. The employment agreement provides for an initial term of one year, with automatic one-year renewal periods unless either the Corporation or Dr. McCann elect to terminate the agreement by providing 60 days' prior notice. If the Corporation terminates Dr. McCann during the initial one-year term without "cause" (as defined in the employment agreement), the employment agreement, which is governed by Delaware law, requires the Corporation to continue to pay Dr. McCann's base salary for the greater of (a) the remainder of the initial one-year term or (b) six months. If the Corporation terminates Dr. McCann without cause during a renewal period, the Corporation must continue to pay Dr. McCann his base salary for a period of 24 months from the date of such termination. In addition, if Dr. McCann resigns due to a substantial change in ownership or in the membership of the Board of Directors, the Corporation must continue to pay Dr. McCann his base salary for a period of one year following the date of such resignation.

On March 18, 2002, the Corporation entered into an employment agreement with its Vice-President of Development Dr. Joseph D. Mosca, pursuant to which Dr. Mosca receives an annual salary of one hundred twenty-five thousand U.S. Dollars ($125,000) and normal benefits. In addition, Dr. Mosca may participate in the Corporation's 2001 Stock Option Plan, as well as receive discretionary bonuses as approved by the Board of Directors. The employment agreement provides for an initial term of one year, with automatic one-year renewal periods unless either the Corporation or Dr. Mosca elect to terminate the agreement by providing 60 days' prior notice. If the Corporation terminates Dr. Mosca during the initial one-year term without "cause" (as defined in the agreement), the employment agreement, which is governed by Delaware law, requires the Corporation to continue to pay Dr. Mosca's his base salary for the greater of
(a) the remainder of the initial one-year term or (b) six months. If the Corporation terminates Dr. Mosca without cause during a renewal period, the Corporation must continue to pay Dr. Mosca his base salary for a period of 12 months from the date of such termination.


ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a)      EXHIBITS

         EXHIBIT
         NUMBER          DESCRIPTION
         ------          -----------

         (3)(i)          Certificate of Incorporation of the Corporation as
                         amended through May 10, 2002
         (3)(ii)         Bylaws of the Corporation(1)
         (10)(i)         Employment Agreement dated March 18, 2002, between Dr.
                         Peter P. McCann and the Corporation(2)
         (10)(ii)        Employment Agreement dated March 18, 2002, between Dr.
                         Joseph D. Mosca and the Corporation
-------------------------

(1) Incorporated by reference to the Corporation's Form 10-Q filed with the Securities and Exchange Commission on August 14, 2001.

(2) Incorporated by reference to the Corporation's Form 10-K filed with the Securities and Exchange Commission on March 29, 2002.

(b) REPORTS ON FORM 8-K

None.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 15, 2002                      MYMETICS CORPORATION

                                            By:      /s/ Peter P. McCann
                                                     --------------------------
                                                     Chief Executive Officer


1
Exhibit 3(i)

CERTIFICATE OF INCORPORATION

OF

ICHOR Corporation

1. The name of the corporation is ICHOR Corporation (the "Corporation").

2. The name of its registered agent is The Corporation Trust Company and the address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801.

3. The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware, as from time to time amended.

4. The total number of shares of all classes of stock which the Corporation shall have authority to issue is Thirty-Five Million (35,000,000) shares, of which Five Million (5,000,000) shares shall be preferred stock, $.01 par value, and Thirty Million (30,000,000) shares shall be common stock, $.0l par value. The preferred stock of the Corporation may be issued from time to time in one or more series. The Board of Directors is expressly authorized, in a resolution or resolutions providing for the issue of such preferred stock, to fix, state and express the powers, rights, designations, preferences, qualifications, limitations and restrictions thereof and to fix the number of shares of such series.

Except as otherwise provided by law, the shares of stock of the Corporation, regardless of class, may be issued by the Corporation from time to time in such amounts, for such consideration and for such corporate purposes as the Corporation's Board of Directors may from time to time determine.

5. In furtherance and not in limitation of the powers conferred by law, the Board of Directors is expressly authorized to make, alter or repeal the By-laws of the Corporation, but any By-laws so made, altered or repealed may be amended or repealed by the stockholders entitled to vote thereon.

6. (a) The Corporation shall, to the fullest extent permitted by
Section 145 of the General Corporation Law of the State of Delaware, as amended from time to time, indemnify every person who is or was a party, or is threatened to be made a party,


2

to (i) any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, or (ii) any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor, by reason of the fact that such person serves or has served at any time as a Director or officer of the Corporation, or who at the request of the Corporation serves or at any time has served as a Director or officer of another corporation (including subsidiaries of the Corporation) or of any partnership, joint venture, trust or other enterprise, from and against any and all of the expenses, liabilities or other matters referred to in or covered by said law. Such indemnification shall continue as to a person who has ceased to be a Director or officer and shall inure to the benefit of the heirs, executors and administrators of such a person. The Corporation may also indemnify any and all other persons whom it shall have power to indemnify under any applicable law from time to time in effect to the extent authorized by the Board of Directors and permitted by such law. The indemnification provided by this Article 6 shall not be deemed exclusive of any other rights to which any person may be entitled under any provision of the Certificate of Incorporation, other By-Law, agreement, vote of stockholders or disinterested Directors, or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office.

(b) To the extent that a director, officer, employee or agent of the Corporation, or a person serving in any other enterprise at the request of the Corporation, shall have been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in subsection (a) of this Article 6 or in defense of any claim, issue or matter therein, he shall be indemnified against all expenses (including attorneys' fees) actually and reasonably paid or incurred by him in connection therewith.

(c) Any indemnification under this Article 6 (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstance because he has met the applicable standard of conduct set forth in this Article 6. Such determination shall be made (1) by the board of directors by a majority vote of a quorum consisting of Directors who were not parties to such action, suit or proceeding, or (2) if such a quorum is not obtainable, or, even if obtainable a quorum of disinterested Directors so directs, by independent legal counsel, who may be one of the regular independent legal counsel of the Corporation, in a written opinion, or (3) by the stockholders.

2

3

(d) Expenses (including attorneys' fees) incurred by a person in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt by the Corporation of an undertaking in writing by or on behalf of the person to be indemnified to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified by the Corporation as authorized in this Article 6. Such expenses (including attorneys' fees) incurred by other employees and agents may be so paid upon such terms and conditions, if any, as the Board of Directors deems appropriate.

(e) The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation. or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the Corporation would have the power to indemnify him against such liability under the provisions of this Article 6.

(f) For purposes of this Article 6, the term "corporation" shall include constituent corporations referred to in Subsection (h) of Section 145 of the General Corporation Law of the State of Delaware (or any similar provision of applicable law at the time in effect), and references to "other enterprises" shall include employee benefit plans.

7. A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (A) for any breach of the director's duty of loyalty to the Corporation or its stockholders, (B) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (C) under Section 174 of the Delaware General Corporation Law or (D) for any transaction from which the director derives an improper personal benefit. If the Delaware General Corporation Law is amended after this Article 7 becomes effective to authorize elimination or limitation of liability of directors, then, upon the effective date of any such amendment, the liability of a director of the Corporation shall, without further

3

4

act, be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law as so amended. Any repeal or modification of this article by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of such repeal or modification.

8. The Corporation shall not be governed by the provisions of Section 203 of the Delaware General corporation Law.

9. In elections for directors, voting need not be by ballot, unless required by vote of the stockholders before the voting for the election of directors begins.

10. The name and mailing address of the incorporator is as follows:

Richard D. Rose One Riverfront Center Pittsburgh, Pennsylvania 15222

I, THE UNDERSIGNED, being the incorporator hereinbefore named, for the purpose of forming a corporation pursuant to the General Corporation Law of the State of Delaware, do make this certificate, hereby declaring and certifying that this my act and deed and the facts herein stated are true, and accordingly have hereunto set my hand this 16th day of September, 1996.

/s/ RICHARD D. ROSE
-------------------------------
Richard D. Rose
Incorporator

4

5

CERTIFICATE OF MERGER
OF
PDG REMEDIATION, INC.
INTO
ICHOR CORPORATION

Pursuant to Section 252 of the

General Corporation Law of the State of Delaware

ICHOR CORPORATION, a corporation organized and existing under the laws of the State of Delaware, does hereby certify:

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger (the "Constituent Corporations") are as

follows;

               Name                                      State of Incorporation
               ----                                      ----------------------
         PDG Remediation, Inc.                                Pennsylvania
         ICHOR Corporation                                    Delaware

SECOND: That an agreement and plan of merger (the "Merger Agreement"), dated as of October 1, 1996, between the Constituent Corporations was approved, adopted, certified, executed and acknowledged by each of the Constituent Corporations in accordance with the requirements of subsection (c) of Section 252 of the General Corporation Law of the State of Delaware and Sections 1921-26 of the Pennsylvania Business Corporation Law of 1988, as amended (15 Pa. C.S. Sections 1921-26).

THIRD: That the name of the corporation surviving the merger is ICHOR Corporation, a Delaware corporation (the "Surviving Corporation").


6

FOURTH: That the Certificate of Incorporation of ICHOR Corporation, as currently in effect, shall be the Certificate of Incorporation of the Surviving Corporation.

FIFTH: That the executed Merger Agreement is on file at the principal place of business of the Surviving Corporation. The address of said principal place of business is 300 Oxford Drive, Monroeville, Pennsylvania 15146.

SIXTH: That a copy of the Merger Agreement will be furnished by the Surviving Corporation, upon request and without cost, to any stockholder or shareholder of any Constituent Entity.

SEVENTH: That the authorized capital stock of each of the Constituent Entities is as follows:

PDG Remediation, Inc.              30,000,000 shares of common
                                   stock, $.01 par value, and
                                   5,000,000 shares of preferred
                                   stock, $.0l par value
ICHOR Corporation                  30,000,000 shares of common
                                   stock, $.01 par value, and
                                   5,000,000 shares of preferred
                                   stock, $.01 par value

IN WITNESS WHEREOF, this Certificate of Merger has been signed by the President and attested by the Assistant Secretary of the Surviving Corporation

this 12th day of November, 1996

ATTEST:                                ICHOR CORPORATION


By /s/ CHRISTINA L. GOETZ                 By /s/ JOHN M. MUSACCHIO
   -------------------------              ---------------------------
Title  Assistant Secretary                Title  President

     -----------------------              ---------------------------
       Christina L. Goetz                     John M. Musacchio


7

CERTIFICATE OF DESIGNATIONS
ICHOR CORPORATION

ICHOR Corporation, a Delaware corporation (the "Corporation"), desires to designate the rights and preferences of a series of preferred stock (the "Series 1 Preferred Stock") in accordance with the Corporation's Certificate of Incorporation and Section 151 o( the Delaware General Corporation Law. Leonard Petersen, Director of the Corporation, hereby certifies the following:

1. This Certificate is the act and deed of Leonard Petersen, Director of the Corporation. The facts stated in this Certificate are true.

2. The resolutions attached as Exhibit A were duly adopted by the board of directors effective March 5, 1998.

3. The number of shares of Series 1 Preferred Stock to which the resolutions at Exhibit A apply is 500,000 shares.

DATED March 5, 1998.

/s/ LEONARD PETERSEN
-----------------------
Leonard Petersen
Director

DATED March 5, 1998.

/s/ KIM C. MOLLER
-----------------------
(Signature of Notary)

KIM C. MOLLER
(Legibly Print or Stamp Name of Notary)

Notary public in and for British Columbia, Canada, residing at Vancouver, British Columbia My commission expires at the pleasure of her majesty the Queen in the Right of the Province of British Columbia


8

EXHIBIT A

DIRECTORS' RESOLUTIONS

BE IT RESOLVED THAT:

1. A first series of Preferred Stock be and is hereby designated as "5% Cumulative Redeemable Convertible Preferred Stock, Series 1" (the "Series 1 Preferred Stock").

2. The number of Series 1 Preferred Stock in the capital of the Corporation be and is hereby fixed at 500,000.

3. The Series 1 Preferred Stock shall have attached thereto the special rights and restrictions, as a series, in substantially the form set out in Schedule "A" hereto, with such changes, additions and alterations thereto as the President or Secretary may deem necessary or desirable, and that the constating documents of the Corporation be amended as necessary to incorporate same.

4. Any one director or officer of the Corporation be and is hereby authorized to execute and deliver the Certificate of Designations relating to the Series 1 Preferred Stock for and on behalf of the Corporation.


9

SCHEDULE "A"

The first series of Preferred Stock, designated 5% Cumulative Redeemable Convertible Preferred Stock, Series 1 (the "Series 1 Shares") shall have attached thereto, in addition to the rights, privileges, restrictions, conditions and limitations attaching to the Preferred Stock as a class, the following rights, privileges, restrictions and conditions (the "Series 1 Provisions"):

1. GENERAL

1.1 DEFINITIONS

Where used in these Series 1 Provisions, the following words and phrases shall, unless there is something in the context otherwise inconsistent therewith, have the following meanings, respectively:

(a) "business day" means a day other than a Saturday, Sunday or any other day treated as a holiday in the State of Delaware;

(b) "close of business" means the normal closing hour of the principal office of the transfer agent for the Series 1 Shares;

(c) "Common Shares" means the Common Shares in the Corporation as such shares were constituted on February 20, 1998, or as such shares may be changed from time to time, provided that any adjustment in the Conversion Rate required by clause 3.5 hereof has been made;

(d) "Conversion Price" means 90% of the Current Market Price;

(e) "Conversion Rate" means at any time means the number of Common Shares into which one Series 1 Share may be converted at such time in accordance with the provisions of Section 3;

(f) "Current Market Price" of the Common Shares on any date means the arithmetic weighted average of the closing prices for sales of Common Shares on the designated exchange based upon the 20 day average closing trading price on the designated exchange, provided that in the event that the Common Shares are not listed on any stock exchange or through any quotation system, Current Market Price shall be determined by the board of directors of the Corporation, which determination shall be conclusive;

(g) "designated exchange" means on any date, the stock exchange or quotation system through which the largest number of Common Shares of the Corporation traded over the 20 trading day period immediately preceding such date;

(h) "director" means a director of the Corporation for the time being and "directors" or "board of directors" means the board of directors of the Corporation or, if duly constituted and empowered, the executive committee of


10

2

the board of directors of the Corporation for the time being, and reference, without further elaboration, to action by the directors means either action by the directors of the Corporation as a board or action by the said executive committee as such committee;

(i) "herein", "hereto", "hereunder", "hereof', "hereby" and similar expressions mean or refer to these Series 1 Provisions and not to any particular Section, clause, subclause, subdivision or portion hereof, and the expressions "Section", "clause" and "subclause" followed by a number or a letter mean and refer to the specified Section, clause or subclause hereof;

(j) "Initial Issue Date" means the first date on which any Series 1 Shares are issued and outstanding;

(k) "Issue Price" means $10.00 per Series 1 Share;

(l) "Junior Shares" means any shares in the capital of the Corporation ranking after or subordinate to the Series 1 Shares as to the payment of dividends or the return of capital, including, without limiting the generality of the foregoing, the Common Shares;

(m) "Liquidation Distribution" means the distribution of assets of the Corporation on the liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, or any other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs;

(n) "ranking as to capital" means ranking or priority with respect to the distribution of assets in the event of a Liquidation Distribution;

(o) "Series 1 Holder" means a person recorded on the securities register of the Corporation as being the registered holder of one or more Series 1 Shares;

(p) "trading day" means any day on which the designated exchange is open for business and on which the relevant class of shares of the Corporation are traded; and

(q) "transfer agent" means the corporation or corporations from time to time appointed by the directors as the transfer agent for the Series 1 Shares and, in the event that no such person is appointed, "transfer agent" means the Corporation.

1.2 GENDER, ETC.

Words importing only the singular number include the plural and vice versa and words importing any gender include all genders.


11

3

1.3 CURRENCY

All monetary amounts referred to herein shall be in lawful money of the United States.

1.4 HEADINGS

The division of these Series 1 Provisions into Sections, clauses, subclauses or other subdivisions and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation hereof.

1.5 BUSINESS DAY

In the event that any date upon which any dividends on the Series 1 Shares are payable by the Corporation, or upon or by which any other action is required to be taken by the Corporation or any Series 1 Holder hereunder, is not a business day, then such dividend shall be payable or such other action shall be required to be taken on or by the next succeeding day which is a business day.

2. DIVIDENDS

2.1 DECLARATION AND PAYMENT OF DIVIDENDS

The holders of Series 1 Shares shall be entitled to receive and the Corporation shall pay thereon, as and when declared by the board of directors out of funds legally available for such purpose, fixed preferential cumulative cash dividends at the rate of $0.50 per share per annum. Such dividends shall accrue, whether or not earned or declared, from and including the date of issue of such shares and, subject as hereinafter provided, shall be payable in equal quarterly installments of $0.125 per share on the last day of each of March, June, September and December in each year (each of which date is hereinafter referred to as a "dividend payment date"). The first dividend payment date shall be March 31, 1998.

2.2 AMOUNT OF DIVIDEND

The amount of the dividend for any period which is less than a full quarter with respect to any Series 1 Share:

(i) which is issued, redeemed or purchased; or

(ii) where assets of the Corporation are distributed to the Series 1 Holders pursuant to Section 6 hereof;

shall be equal to the amount calculated by multiplying $0.125 by a fraction the numerator of which is the number of days in such quarter for which such share has been outstanding (including the dividend payment date at the beginning of such quarter if such share was outstanding on that date excluding the next succeeding dividend payment date if such share was outstanding on that date), and the denominator of which is the number of days in such quarter (including the dividend payment date at the beginning thereof and excluding the next succeeding dividend payment date).


12

4

The amount of dividend payable in respect of each Series 1 Share on the first dividend payment date following the Initial Issue Date shall be that proportion of $0.125 which the number of days from and including the Initial Issue Date to but excluding such dividend payment date is to the total number of days in the 3 month period immediately preceding such dividend payment date.

2.3 CUMULATION OF DIVIDENDS

If on any dividend payment date a dividend accrued to and payable on such date is not paid in full on the Series 1 Shares then issued and outstanding, the dividend or the unpaid part thereof shall be paid on a subsequent dividend payment date or dividend payment dates determined by the board of directors on which the Corporation shall have sufficient moneys legally available for the payment of the same. The Series 1 Holders shall not be entitled to any dividends other than or in excess of the fixed preferential cumulative dividends provided for in this Section 2.

3. CONVERSION

3.1 RIGHT TO CONVERT

Upon and subject to the terms and conditions hereinafter set forth, the holders of Series 1 Shares shall have the right, at any time and from time to time, up to the close of business on March 6, 2003, or, in the case of Series 1 Shares called for redemption, to the close of business on the business day immediately preceding the date fixed for redemption, whichever is earlier (provided, however, that if the Corporation shall fail to redeem such Series 1 Shares in accordance with the notice of redemption the right of conversion shall thereupon be restored as if such call for redemption had not been made), to convert all or any part of their Series 1 Shares into fully paid and non-assessable Common Shares, at the Conversion Rate in effect on the date of conversion. Unless and until adjusted in accordance with these Series 1 Provisions, the Conversion Rate shall be equal to the quotient obtained when the Issue Price plus all accrued and unpaid dividends thereon outstanding as at the date of conversion is divided by the Conversion Price.

3.2 CONVERSION PROCEDURE

The conversion right provided for in clause 3.1 may be exercised by completing and executing a notice of conversion on the certificate or certificates representing the Series 1 Shares in respect of which the holder thereof desires to exercise such right of conversion or such other form of notice approved by the Corporation and by delivering the said notice and certificate or certificates to the transfer agent for the Series 1 Shares at any office for the transfer of the Series 1 Shares. The said notice of conversion shall be signed by such holder or by his duly authorized attorney or agent with signature guaranteed in a manner satisfactory to the transfer agent and shall specify the number of Series 1 Shares which the Series 1 Holder desires to have converted.


13

5

The transfer form in the certificate or certificates in question need not be endorsed, except in the circumstances contemplated by clause 3.3. If less than all the Series 1 Shares represented by a certificate or certificates are to be converted, the Series 1 Holder shall be entitled to receive, at the expense of the Corporation, a new certificate representing the Series 1 Shares represented by the certificate or certificates surrendered as aforesaid which are not to be converted.

3.3 PERSON TO WHOM COMMON SHARES WILL BE ISSUED

On any conversion of Series 1 Shares the share certificates for Common Shares resulting therefrom shall be issued at the expense of the Corporation in the name of the registered holder of the Series 1 Shares converted or in such name or names as such registered holder may direct in writing, provided that such registered holder shall pay any applicable security transfer taxes. In any case where the Common Shares are to be issued in the name at a person other than the holder of the converted Series 1 Shares, the transfer form on the back of the certificates in question shall be endorsed by the registered holder of the Series 1 Shares or his duly authorized attorney or agent, with signature guaranteed in a manner satisfactory to the transfer agent.

3.4 EFFECTIVE DATE OF CONVERSION

Each Series 1 Holder whose shares are to be converted in whole or in part (or any other person or persons in whose name or names any certificates representing Common Shares are issued as provided in clause 3.3) shall be deemed to have become the holder of record of the Common Shares into which such Series 1 Shares are converted, for all purposes, on the respective dates of receipt by the transfer agent of the certificate or certificates representing the Series 1 Shares to be converted as provided in clause 3.2, notwithstanding any delay in the delivery of the certificate or certificates representing the Common Shares into which such Series 1 Shares have been converted and, effective as of and throughout such respective dates, the Series 1 Holder shall cease to be registered as the holder of record of the Series 1 Shares so converted.

3.5 ADJUSTMENT OF CONVERSION RATE

3.5.1    If and whenever at any time and from time to time the Corporation shall
         (i) subdivide, redivide or change its then outstanding Common Shares
         into a greater number of Common Shares, (ii) reduce, combine or
         consolidate or change its then outstanding Common Shares into a lesser
         number of Common Shares, or (iii) issue Common Shares (or securities
         exchangeable or convertible into Common Shares) to the holders of all
         or substantially all of its then outstanding Common Shares by way of
         stock dividend or other distribution (other than a stock dividend paid
         in the ordinary course) (any of such events being herein called a
         "Common Share Reorganization"), the Conversion Rate shall be adjusted
         effective immediately after the record date at which the holders of
         Common Shares are determined for the purpose of the Common Share
         Reorganization to provide that each Series 1 Holder shall thereafter be
         entitled to receive such number of Common Shares as he would have been
         entitled to receive had he exercised his conversion rights immediately
         prior to such Common Share Reorganization.


14

6

3.5.2    If and whenever there is a capital reorganization of the Corporation
         not otherwise provided for in this clause 3.5 or a consolidation,
         merger, arrangement or amalgamation (statutory or otherwise) of the
         Corporation with or into another body corporate (any such event being
         called a "Capital Reorganization"), any Series 1 Holder who has not
         exercised his right of conversion prior to the record date for such
         Capital Reorganization shall be entitled to receive and shall accept,
         upon the exercise of such right at any time after the record date for
         such Capital Reorganization, in lieu of the number of Common Shares to
         which he was theretofore entitled upon conversion, the aggregate number
         of shares or other securities of the Corporation or of the corporation
         or body corporate resulting, surviving or continuing from the Capital
         Reorganization that such holder would have been entitled to receive as
         a result of such Capital Reorganization if, on the record date, he had
         been the registered holder of the number of Common Shares to which he
         was theretofore entitled upon conversion, subject to adjustment
         thereafter in accordance with provisions the same, as nearly as may be
         possible, as those contained in this clause 3.5; provided that no such
         Capital Reorganization shall be carried into effect unless all
         necessary steps shall have been taken so that the Series 1 Holder shall
         thereafter be entitled to receive such number of shares or other
         securities of the Corporation or of the corporation or body corporate
         resulting, surviving or continuing from the Capital Reorganization.

3.5.3    In case of any reclassification of, or other change in, the outstanding
         Common Shares other than a Common Share Reorganization or a Capital
         Reorganization, the right of conversion shall be adjusted immediately
         after the record date for such reclassification or other change so that
         Series 1 Holders shall be entitled to receive, upon the exercise of
         such right at any time after the record date of such reclassification
         or other change, such shares, securities or rights as they would have
         received had such Series 1 Shares been converted into Common Shares
         immediately prior to such record date subject to adjustment thereafter
         in accordance with provisions, the same as nearly may be possible, as
         those contained in this clause 3.5.

3.6      ENTITLEMENT TO DIVIDENDS

         Each Series 1 Holder on the record date for any dividend declared

payable on the Series 1 Shares shall be entitled to such dividend notwithstanding that any Series 1 Share owned by him is converted after such record date and before the payment date of such dividend. The registered holder of any Common Share resulting from any conversion effected pursuant to this
Section 3 shall be entitled to rank equally with the registered holders of all other Common Shares in respect of all dividends declared payable to holders of Common Shares of record on or after the date of conversion.

3.7 AVOIDANCE OF FRACTIONAL SHARES

In any case where a fraction of a Common Share would otherwise be issuable on conversion of one or more Series 1 Shares, the Corporation shall, at its option, either (i) adjust such fractional interest by payment by check in an amount equal to the then current market value of such fractional interest or
(ii) issue in respect of such fraction a scrip certificate transferable by delivery entitling the holder


15

7

thereof and of other similar certificates aggregating one full Common Share, upon surrender of such certificates at such place as may be designated therein, to obtain from the Corporation a full Common Share and to receive a share certificate therefor; such checks shall be payable to the holders thereof in lawful money of the United States at par at any branch in the United States of the Corporation's bankers for the time being and such scrip certificates shall be in such form and shall be subject to such terms and conditions as the directors may determine and shall provide that the holder thereof shall not thereby be a shareholder and shall not be entitled to receive dividends or to any other rights of a shareholder. The amount of any cash adjustment shall equal the current market value of such fractional interest computed on the basis of the last sale price (or average of the bid and asked prices if there were no sales) per share for the Common Shares on the NASDAQ Stock Market (or, if such shares are not then listed and posted for trading on such stock exchange, on such stock exchange or quotation system through which such shares are listed and posted for trading as may be selected by the board of directors) on the business day next preceding the conversion date. In the event that the Common Shares of the Corporation are not listed on any stock exchange or through any quotation system the current market value shall be determined by the board of directors which determination shall be conclusive.

4. REDEMPTION

4.1 OPTIONAL REDEMPTION

4.1.1    The Corporation, upon giving notice as hereinafter provided, may redeem
         all at any time and part from time to time of the then outstanding
         Series 1 Shares, on payment for each share to be redeemed of the Issue
         Price together in each case with an amount equal to all accrued and
         unpaid cumulative preferential dividends thereon calculated to but
         excluding the date fixed for redemption, the whole constituting and
         herein referred to as the "Redemption Price". The Redemption Price
         shall be adjusted in the event of any subdivision, redivision,
         reduction, combination or consolidation of the outstanding Series 1
         Shares to provide that the Series 1 Holders shall thereafter be
         entitled to receive the same amount in respect of the Redemption Price
         as they would have been entitled to receive had the Corporation
         redeemed the Series 1 Shares prior to the occurrence of any such event.

4.2      PARTIAL REDEMPTION

         If less than all the Series 1 Shares are at any time to be redeemed,

the shares to be redeemed shall be selected by lot or in such other manner as the board of directors may deem equitable or, if the board of directors so determines, on a pro rata basis, disregarding fractions, according to the number of Series 1 Shares held by each of the registered holders thereof. If less than all of the Series 1 Shares are at any time to be redeemed and a Series 1 Holder has duly exercised his right to convert into Common Shares all or any part of the number of Series 1 Shares held by such holder which have been called for redemption, the number of Series 1 Shares held by such Series 1 Holder to be redeemed shall be reduced by the number (but not exceeding the number of Series 1 Shares held by such Series 1 Holder called for redemption) of Series 1 Shares in respect of which such registered holder has duly exercised his right to convert into Common Shares. If only a part of the Series 1 Shares


16

8

represented by any certificate shall be redeemed, a new certificate representing the balance of such shares shall be issued to the holder thereof at the expense of the Corporation upon presentation and surrender of the first mentioned certificate.

4.3 METHOD OF REDEMPTION

4.3.1    In any case of redemption of Series 1 Shares, the Corporation shall not
         less than 10 days and not more than 45 days before the date specified
         for redemption send by prepaid first class mail or deliver to the
         registered address of each person who at the date not more than 50 days
         prior to the date of mailing or delivery is a Series 1 Holder to be
         redeemed a notice in writing of the intention of the Corporation to
         redeem the Series 1 Shares registered in the name of such holder.
         Accidental failure or omission to give such notice to one or more
         holders shall not affect the validity of such redemption, but upon such
         failure or omission being discovered notice shall be given forthwith to
         such holder or holders and such notice shall have the same force and
         effect as if given in due time. Such notice shall set out the number of
         Series 1 Shares held by the person to whom it is addressed which are to
         be redeemed, the Redemption Price, the that specified for redemption
         and the place or places at which holders of Series 1 Shares may present
         and surrender such shares for redemption.

4.3.2    On the date so specified for redemption, the Corporation shall pay or
         cause to be paid to or to the order of the Series 1 Holders to be
         redeemed the Redemption Price of such shares on presentation and
         surrender of the certificate or certificates representing the Series 1
         Shares called for redemption at the registered office of the
         Corporation or any other place or places specified in the notice of
         redemption. Payment in respect of Series 1 Shares being redeemed shall
         be made by check payable to the holder thereof in lawful money of the
         United States at par at any branch in the United States of the
         Corporation's bankers for the time being.

4.3.3    From and after the date specified for redemption in any such notice of
         redemption, the Series 1 Shares called for redemption shall cease to be
         entitled to dividends or any other participation in the assets of the
         Corporation and the holders thereof shall not be entitled to exercise
         any of their other rights as shareholders in respect thereof unless
         payment of the Redemption Price shall not be made upon presentation and
         surrender of the certificates in accordance with the foregoing
         provisions, in which case the rights of the holders shall remain
         unaffected.

4.3.4    The Corporation shall have the right at any time on or after the
         mailing or delivery of notice of its intention to redeem Series 1
         Shares to deposit the Redemption Price of the Series 1 Shares so called
         for redemption, or of such of the Series 1 Shares which are represented
         by certificates which have not at the date of such deposit been
         surrendered by the holders thereof in connection with such redemption,
         to a special account in any specified United States bank named in such
         notice of redemption or in a subsequent notice to the registered
         holders of the shares in respect of which the deposit is made, to be
         paid without interest to or to the order of the respective Series 1
         Holders whose shares have been called for redemption, upon presentation


17

9

         and surrender to such bank of the certificates representing such
         shares. Upon such deposit being made, the Series 1 Shares in respect of
         which such deposit shall have been made shall be deemed to have been
         redeemed and the rights of the holders thereof after such shall be
         limited to receiving their proportion (less any tax required to be
         deducted or withheld therefrom) of the amount so deposited without
         interest upon presentation and surrender of the certificate or
         certificates representing the Series 1 Shares being redeemed. Any
         interest allowed on any such deposit shall belong to the Corporation.

4.3.5    Redemption moneys that are represented by a check which has not been
         presented to the Corporation's bankers for payment or that otherwise
         remain unclaimed (including moneys held on deposit in a special account
         as provided for above) for a period of 5 years from the date specified
         for redemption shall be forfeited to the Corporation.

5.       RESTRICTIONS ON DIVIDENDS, RETIREMENT AND ISSUANCE OF SHARES While any
         Series 1 Shares are outstanding, the Corporation shall not, without the
         approval of the holders of Series 1 Shares given as hereinafter
         specified:

(a)      declare, set aside for payment or pay any dividends on or make
         distributions on or in respect of any Junior Shares (other than
         dividends consisting of Junior Shares); or

(b)      call for redemption, redeem, purchase, retire or acquire for value or
         distribute in respect of any Junior Shares (except to the extent and
         out of net cash proceeds received by the Corporation from a
         substantially concurrent issue of Junior Shares); or

(c)      call for redemption, redeem, purchase or otherwise retire or acquire
         for value less than all of the Series 1 Shares outstanding; unless, in
         each such case, all dividends then payable on the Series 1 Shares then
         outstanding accrued up to and including the dividends payable on the
         immediately preceding respective date or dates for the payment of
         dividends thereon shall have been declared and paid or set apart for
         payment or unless such action has been approved by the Series 1
         Holders.

6.       LIQUIDATION, DISSOLUTION OR WINDING-UP

         In the event of any Liquidation Distribution, each Series 1 Holder

shall be entitled to receive before any amount shall be paid by the Corporation or any assets of the Corporation shall be distributed to registered holders of shares ranking as to capital junior to the Series 1 Shares in connection with the Liquidation Distribution, an amount equal to the stated capital per share of all Series 1 Shares held by such holder, together with an amount equal to all accrued but unpaid cumulative dividends thereon. After payment to the Series 1 Holders of the amount so payable to them, they shall not be entitled to share in any further distribution of assets of the Corporation.


18

10

7. VOTING RIGHTS

Except as otherwise required by law, the holders of the Series 1 Shares shall not be entitled, as such, to receive notice of or attend or vote at any meeting of shareholders of the Corporation other than a meeting of Series 1 Holders.

8. AMENDMENTS TO SERIES 1 PROVISIONS

These Series 1 Provisions may be repealed, altered, modified, amended or varied only with the prior approval of the holders of the Series 1 Shares given in the manner provided in Section 9 hereof in addition to any other approval required by any statutory provision of like or similar effect applicable to the Corporation from time to time in force.

9. CONSENTS AND APPROVALS

9.1 The approval of the Series 1 Holders with respect to any and all matters may be given by one or more consents in writing signed by the holders of at least 2/3 of the issued and outstanding Series 1 Shares or by a resolution passed by at least 2/3 of the votes cast at a meeting of the Series 1 Holders duly called for that purpose and held upon at least 10 days' notice, at which the holders of at least 1/3 of the outstanding Series 1 Shares are present or represented by proxy. If at any such meeting the holders of 1/3 of the outstanding Series 1 Shares are not present or represented by proxy within one-half hour after the time appointed for such meeting, then the meeting may be adjourned to such date being not less than 7 days later and to such time and place as may be appointed by the chairman of the meeting.

9.2 The formalities to be observed with respect to the giving of notice of any such meeting and the conduct thereof shall be those from time to time prescribed by the by-laws of the Corporation with respect to meetings of shareholders.

9.3 On every vote taken at every such meeting or adjourned meeting every Series 1 Holder shall be entitled to one vote in respect of each Series 1 Share of which he is the registered holder.

10. NOTICES

10.1 Any notice required or permitted to be given to any Series 1 Holder shall be sent by first class mail, postage prepaid, or delivered to such holder at his address as it appears on the records of the Corporation or, in the event of the address of any such shareholder not so appearing, to the last known address of such shareholder. The accidental failure to give notice to one or more of such shareholders shall not affect the validity of any action requiring the giving of notice by the Corporation. Any notice given as aforesaid shall be deemed to be given on the date upon which it is mailed or delivered.


19

CERTIFICATE OF DESIGNATIONS
ICHOR CORPORATION

ICHOR Corporation, a Delaware corporation (the "Corporation"), desires to designate the rights and preferences of a series of preferred stock (the "Series 2 Preferred Stock") in accordance with the Corporation's Certificate of Incorporation and Section 151 of the Delaware General Corporation Law. Roy Zanatta, Director of the Corporation, hereby certifies the following:

1. This Certificate is the act and deed of Roy Zanatta, Director of the Corporation. The facts stated in this Certificate are true.

2. The resolutions attached as Exhibit A were duly adopted by the board of directors effective November 30, 1999.

3. The number of shares of Series 2 Preferred Stock to which the resolutions at Exhibit A apply is 100,000 shares.

DATED December 6, 1999.

/s/ ROY ZANATTA
--------------------------
Roy Zanatta
Director

DATED December 6, 1999.

/s/ KARIN LALANI
--------------------------
(Signature of Notary)

KARIN LALANI
(Legibly Print or Stamp Name of Notary)

Notary public in and for British Columbia,
Canada, residing at Vancouver, British
Columbia

My commission expires at the pleasure of
her majesty the Queen in the Right of the
Province of British Columbia


20

EXHIBIT A

DIRECTORS' RESOLUTIONS

BE IT RESOLVED THAT:

1. A second series of Preferred Stock be and is hereby designated as "5% Cumulative Redeemable Convertible Preferred Stock, Series 2" (the "Series 2 Preferred Stock").

2. The number of Series 2 Preferred Stock in the capital of the Corporation be and is hereby fixed at 100,000.

3. The Series 2 Preferred Stock shall have attached thereto the special rights and restrictions, as a series, in substantially the form set out in Schedule "A" hereto, with such changes, additions and alterations thereto as the President or Secretary may deem necessary or desirable, and that the constating documents of the Corporation be amended as necessary to incorporate same.

4. Any one director or officer of the Corporation be and is hereby authorized to execute and deliver the Certificate of Designations relating to the Series 2 Preferred Stock for and on behalf of the Corporation.


21

SCHEDULE "A"

The second series of Preferred Stock, designated 5% Cumulative Redeemable Convertible Preferred Stock, Series 2 (the "Series 2 Shares") shall have attached thereto, in addition to the rights, privileges, restrictions, conditions and limitations attaching to the Preferred Stock as a class, the following rights, privileges, restrictions and conditions (the "Series 2 Provisions"):

1. GENERAL

1.1 DEFINITIONS

Where used in these Series 2 Provisions, the following words and phrases shall, unless there is something in the context otherwise inconsistent therewith, have the following meanings, respectively:

(a) "business day" means a day other than a Saturday, Sunday or any other day treated as a holiday in the State of Delaware;

(b) "close of business" means the normal closing hour of the principal office of the transfer agent for the Series 2 Shares;

(c) "Common Shares" means the Common Shares in the Corporation as such shares were constituted on November 30, 1999, or as such shares may be changed from time to time, provided that any adjustment in the Conversion Rate required by clause 3.5 hereof has been made;
(d) "Conversion Price" means 90% of the Current Market Price;

(e) "Conversion Rate" means at any time the number of Common Shares into which one Series 2 Share maybe converted at such time in accordance with the provisions of Section 3;

(f) "Current Market Price" of the Common Shares on any date means the arithmetic weighted average of the closing prices for sales of Common Shares on the designated exchange based upon the 20 day average closing trading price on the designated exchange, provided that in the event that the Common Shares are not listed on any stock exchange or through any quotation system, Current Market Price shall be determined by the board of directors of the Corporation, which determination shall be conclusive;

(g) "designated exchange" means on any date, the stock exchange or quotation system through which the largest number of Common Shares of the Corporation traded over the 20 trading day period immediately preceding such date;

(h) "director" means a director of the Corporation for the time being and "directors" or "board of directors" means the board of directors of the Corporation or, if duly constituted and empowered, the executive committee of


22

2

the board of directors of the Corporation for the time being, and reference, without further elaboration, to action by the directors means either action by the directors of the Corporation as a board or action by the said executive committee as such committee;

(i) "herein", "hereto", "hereunder", "hereof", "hereby" and similar expressions mean or refer to these Series 2 Provisions and not to any particular Section, clause, subclause, subdivision or portion hereof, and the expressions "Section", "clause" and "subclause" followed by a number or a letter mean and refer to the specified Section, clause or subclause hereof;

(j) "Initial Issue Date" means the first date on which any Series 2 Shares are issued and outstanding;

(k) "Issue Price" means $10.00 per Series 2 Share;

(l) "Junior Shares" means any shares in the capital of the Corporation ranking after or subordinate to the Series 2 Shares as to the payment of dividends or the return of capital, including, without limiting the generality of the foregoing, the Common Shares;

(m) "Liquidation Distribution" means the distribution of assets of the Corporation on the liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, or any other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs;

(n) "ranking as to capital" means ranking or priority with respect to the distribution of assets in the event of a Liquidation Distribution;

(o) "Series 1 Shares" means the first series of Preferred Stock, designated 5% Cumulative Redeemable Convertible Preferred Stock, Series 1, of which 467,500 are issued and outstanding as at November 30, 1999;

(p) "Series 1 Holder" means a person recorded in the securities register of the Corporation as being the registered holder of one or more Series 1 Shares;

(q) "Series 2 Holder" means a person recorded on the securities register of the Corporation as being the registered holder of one or more Series 2 Shares;

(r) "trading day" means any day on which the designated exchange is open for business and on which the relevant class of shares of the Corporation are traded; and

(s) "transfer agent" means the corporation or corporations from time to time appointed by the directors as the transfer agent for the Series 2 Shares and, in the event that no such person is appointed, "transfer agent" means the Corporation.


23

3

1.2 GENDER, ETC.

Words importing only the singular number include the plural and vice versa and words importing any gender include all genders.

1.3 CURRENCY

All monetary amounts referred to herein shall be in lawful money of the United States.

1.4 HEADINGS

The division of these Series 2 Provisions into sections, clauses, subclauses or other subdivisions and the insertion of headings are for convenience of reference only and shall not affect the construction or interpretation hereof.

1.5 BUSINESS DAY

In the event that any date upon which any dividends on the Series 2 Shares are payable by the Corporation, or upon, or by which any other action is required to be taken by the Corporation or any Series 2 Holder hereunder, is not a business day, then such dividend shall be payable or such other action shall be required to be taken on or by the next succeeding day which is a business day.

2. DIVIDENDS

2.1 DECLARATION AND PAYMENT OF DIVIDENDS

The holders of Series 2 Shares shall be entitled to receive and the Corporation shall pay thereon, as and when declared by the board of directors out of funds legally available for such purpose, fixed preferential cumulative cash dividends at the rate of $0.50 per share per annum. Such dividends shall accrue, whether or not earned or declared, from and including the date of issue of such shares and, subject as hereinafter provided, shall be payable in equal quarterly installments of $0.125 per share on the last day of each of March, June, September and December in each year (each of which date is hereinafter referred to as a "dividend payment date"). The first dividend payment date shall be December 31, 1999. In the event that the Corporation does not have sufficient funds legally available for the purpose of payment of dividends to allow full payment of dividends to Series 1 Holders and Series 2 Holders on any dividend payment date, payment of dividends on such date shall be made pro rata and pari passu to the holders of the Series 1 Shares and the Series 2 Shares.


24

4

2.2 AMOUNT OF DIVIDEND

The amount of the dividend for any period which is less than a full quarter with respect to any Series 2 Share:

(i) which is issued, redeemed or purchased; or

(ii) where assets of the Corporation are distributed to the Series 2 Holders pursuant to Section 6 hereof;

shall be equal to the amount calculated by multiplying $0.125 by a fraction the numerator of which is the number of days in such quarter for which such share has been outstanding (including the dividend payment date at the beginning of such quarter if such share was outstanding on that date excluding the next succeeding dividend payment date if such share was outstanding on that date), and the denominator of which is the number of days in such quarter (including the dividend payment date at the beginning thereof and excluding the next succeeding dividend payment date).

The amount of dividend payable in respect of each Series 2 Share on the first dividend payment date following the Initial Issue Date shall be that proportion of $0.125 which the number of days from and including the Initial Issue Date to but excluding such dividend payment date is to the total number of days in the 3 month period immediately preceding such dividend payment date.

2.3 CUMULATION OF DIVIDENDS

If on any dividend payment date a dividend accrued to and payable on such date is not paid in full on the Series 2 Shares then issued and outstanding, the dividend or the unpaid part thereof shall be paid on a subsequent dividend payment date or dividend payment dates determined by the board of directors on which the Corporation shall have sufficient moneys legally available for the payment of the same. The Series 2 Holders shall not be entitled to any dividends other than or in excess of the fixed preferential cumulative dividends provided for in this Section 2.

3. CONVERSION

3.1 RIGHT TO CONVERT

Upon and subject to the terms and conditions hereinafter set forth, the holders of Series 2 Shares shall have the right, at any time and from time to time, up to the close of business on November 30, 2004, or, in the case of Series 2 Shares called for redemption, to the close of business on the business day immediately preceding the date fixed for redemption, whichever is earlier (provided, however, that if the Corporation shall fail to redeem such Series 2 Shares in accordance with the notice of redemption the right of conversion shall thereupon be restored as if such call for redemption had not been made), to convert all or any part of their Series 2 Shares into fully paid and non-assessable Common Shares, at the Conversion Rate in effect on the date of conversion. Unless and until adjusted in accordance with these


25

5

Series 2 Provisions, the Conversion Rate shall be equal to the quotient obtained when the Issue Price plus all accrued and unpaid dividends thereon outstanding as at the date of conversion is divided by the Conversion Price.

3.2 CONVERSION PROCEDURE

The conversion right provided for in clause 3.1 may be exercised by completing and executing a notice of conversion on the certificate or certificates representing the Series 2 Shares in respect of which the holder thereof desires to exercise such right of conversion or such other form of notice approved by the Corporation and by delivering the said notice and certificate or certificates to the transfer agent for the Series 2 Shares at any office for the transfer of the Series 2 Shares. The said notice of conversion shall be signed by such holder or by his duly authorized attorney or agent, with signature guaranteed in a manner satisfactory to the transfer agent and shall specify the number of Series 2 Shares which the Series 2 Holder desires to have converted. The transfer form in the certificate or certificates in question need not be endorsed, except in the circumstances contemplated by clause 3.3. If loss than all the Series 2 Shares represented by a certificate or certificates are to be converted, the Series 2 Holder shall be entitled to receive, at the expense of the Corporation, a new certificate representing the Series 2 Shares represented by the certificate or certificates surrendered as aforesaid which are not to be converted.

3.3 PERSON TO WHOM COMMON SHARES WILL BE ISSUED

On any conversion of Series 2 Shares the share certificates for Common Shares resulting therefrom shall be issued at the expense of the Corporation in the name of the registered holder of the Series 2 Shares converted or in such name or names as such registered holder may direct in writing, provided that such registered holder shall pay any applicable security transfer taxes. In any case where the Common Shares are to be issued in the name of a person other than the holder of the converted Series 2 Shares, the transfer form on the back of the certificates in question shall be endorsed by the registered holder of the Series 2 Shares or his duly authorized attorney or agent, with signature guaranteed in a manner satisfactory to the transfer agent.

3.4 EFFECTIVE DATE OF CONVERSION

Each Series 2 Holder whose shares are to be converted in whole or in part (or any other person or persons in whose name or names any certificates representing Common Shares are issued as provided in clause 3.3) shall be deemed to have become the holder of record of the Common Shares into which such Series 2 Shares are converted, for all purposes, on the respective dates of receipt by the transfer agent of the certificate or certificates representing the Series 2 Shares to be converted as provided in clause 3.2, notwithstanding any delay in the delivery of the certificate or certificates representing the Common Shares into which such Series 2 Shares have been converted and, effective as of and throughout such respective dates, the Series 2 Holder shall cease to be registered as the holder of record of the Series 2 Shares so converted.


26

6

3.5 ADJUSTMENT OF CONVERSION RATE

3.5.1    If and whenever at any time and from time to time the Corporation shall
         (i) subdivide, redivide or change its then outstanding Common Shares
         into a greater number of Common Shares, (ii) reduce, combine or
         consolidate or change its then outstanding Common Shares into a lesser
         number of Common Shares, or (iii) issue Common Shares (or securities
         exchangeable or convertible into Common Shares) to the holders of all
         or substantially all of its then outstanding Common Shares by way of
         stock dividend or other distribution (other than a stock dividend paid
         in the ordinary course) (any of such events being herein called a
         "Common Share Reorganization"), the Conversion Rate shall be adjusted
         effective immediately after the record date at which the holders of
         Common Shares are determined for the purpose of the Common Share
         Reorganization to provide that each Series 2 Holder shall thereafter be
         entitled to receive such number of Common Shares as he would have been
         entitled to receive had he exercised his conversion rights immediately
         prior to such Common Share Reorganization.

3.5.2    If and whenever there is a capital reorganization of the Corporation
         not otherwise provided for in this clause 3.5 or a consolidation,
         merger, arrangement or amalgamation (statutory or otherwise) of the
         Corporation with or into another body corporate (any such event being
         called a "Capital Reorganization"), any Series 2 Holder who has not
         exercised his right of conversion prior to the record date for such
         Capital Reorganization shall be entitled to receive and shall accept,
         upon the exercise of such right at any time after the record date for
         such Capital Reorganization, in lieu of the number of Common Shares to
         which he was theretofore entitled upon conversion, the aggregate number
         of shares or other securities of the Corporation or of the corporation
         or body corporate resulting, surviving or continuing from the Capital
         Reorganization that such holder would have been entitled to receive as
         a result of such Capital Reorganization if, on the record date, he had
         been the registered holder of the number of Common Shares to which he
         was theretofore entitled upon conversion, subject to adjustment
         thereafter in accordance with provisions the same, as nearly as may be
         possible, as those contained in this clause 3.5; provided that no such
         Capital Reorganization shall be carried into effect unless all
         necessary steps shall have been taken so that the Series 2 Holder shall
         thereafter be entitled to receive such number of shares or other
         securities of the Corporation or of the corporation or body corporate
         resulting, surviving or continuing from the Capital Reorganization.

3.5.3    In case of any reclassification of, or other change in, the outstanding
         Common Shares other than a Common Share Reorganization or a Capital
         Reorganization, the right of conversion shall be adjusted immediately
         after the record date for such reclassification or other change so that
         Series 2 Holders shall be entitled to receive, upon the exercise of
         such right at any time after the record date of such reclassification
         or other change, such shares, securities or rights as they would have
         received had such Series 2 Shares been converted into Common Shares
         immediately prior to such record date subject to adjustment thereafter
         in accordance with provisions, the same as nearly may be possible, as
         those contained in this clause 3.5.


27

7

3.6 ENTITLEMENT TO DIVIDENDS

Each Series 2 Holder on the record date for any dividend declared payable on the Series 2 Shares shall be entitled to such dividend notwithstanding that any Series 2 Share owned by him is converted after such record date and before the payment date of such dividend. The registered holder of any Common Share resulting from any conversion effected pursuant to this
Section 3 shall be entitled to rank equally with the registered holders of all other Common Shares in respect of all dividends declared payable to holders of Common Shares of record on or after the date of conversion.

3.7 AVOIDANCE OF FRACTIONAL SHARES

In any case where a fraction of a Common Share would otherwise be issuable on conversion of one or more Series 2 Shares, the Corporation shall, at its option, either (i) adjust such fractional interest by payment by check in an amount equal to the then current market value of such fractional interest or
(ii) issue in respect of such fraction a scrip certificate transferable by delivery entitling the holder thereof and of other similar certificates aggregating one full Common Share, upon surrender of such certificates at such place as may be designated therein, to obtain from the Corporation a full Common Share and to receive a share certificate therefor; such checks shall be payable to the holders thereof in lawful money of the United States at par at any branch in the United States of the Corporation's bankers for the time being and such scrip certificates shall be in such form and shall be subject to such terms and conditions as the directors may determine and shall provide that the holder thereof shall not thereby be a shareholder and shall not be entitled to receive dividends or to any other rights of a shareholder. The amount of any cash adjustment shall equal the current market value of such fractional interest computed on the basis of the last sale price (or avenge of the bid and asked prices if there were no sales) per share for the Common Shares on the NASDAQ Stock Market (or, if such shares are not then listed and posted for trading on such stock exchange, on such stock exchange or quotation system through which such shares are listed and posted for trading as may be selected by the board of directors) on the business day next preceding the conversion date. In the event that the Common Shares of the Corporation are not listed on any stock exchange or through any quotation system the current market value shall be determined by the board of directors which determination shall be conclusive.

4. REDEMPTION

4.1 OPTIONAL REDEMPTION

4.1.1    The Corporation, upon giving notice as hereinafter provided, may redeem
         all at any time and part from time to time of the then outstanding
         Series 2 Shares, on payment for each share to be redeemed of the Issue
         Price together in each ease with an amount equal to all accrued and
         unpaid cumulative preferential dividends thereon calculated to but
         excluding the date fixed for redemption, the whole constituting and
         herein referred to as the "Redemption Price". The Redemption Price


28

8

shall be adjusted in the event of any subdivision, redivision, reduction, combination or consolidation of the outstanding Series 2 Shares to provide that the Series 2 Holders shall thereafter be entitled to receive the same amount in respect of the Redemption Price as they would have been entitled to receive had the Corporation redeemed the Series 2 Shares prior to the occurrence of any such event.

4.2 PARTIAL REDEMPTION

If less than all the Series 2 Shares are at any time to be redeemed, the shares to be redeemed shall be selected by lot or in such other manner as the board of directors may deem equitable or, if the board of directors so determines, on a pro rata basis, disregarding fractions, according to the number of Series 2 Shares held by each of the registered holders thereof. If less than all of the Series 2 Shares are at any time to be redeemed and a Series 2 Holder has duly exercised his right to convert into Common Shares all or any part of the number of Series 2 Shares held by such holder which have been called for redemption, the number of Series 2 Shares held by such Series 2 Holder to be redeemed shall be reduced by the number (but not exceeding the number of Series 2 Shares held by such Series 2 Holder called for redemption) of Series 2 Shares in respect of which such registered holder has duly exercised his right to convert into Common Shares. If only a part of the Series 2 Shares represented by any certificate shall be redeemed, a new certificate representing the balance of such shares shall be issued to the holder thereof at the expense of the Corporation upon presentation and surrender of the first mentioned certificate.

4.3 METHOD OF REDEMPTION

4.3.1    In any case of redemption of Series 2 Shares, the Corporation shall not
         less than 10 days and not more than 45 days before the date specified
         for redemption send by prepaid first class mail or deliver to the
         registered address of each person who at the date not more than 50 days
         prior to the date of mailing or delivery is a Series 2 Holder to be
         redeemed a notice in writing of the intention of the Corporation to
         redeem the Series 2 Shares registered in the name of such holder.
         Accidental failure or omission to give such notice to one or more
         holders shall not affect the validity of such redemption, but upon such
         failure or omission being discovered notice shall be given forthwith to
         such holder or holders and such notice shall have the same force and
         effect as if given in due time. Such notice shall set out the number of
         Series 2 Shares held by the person to whom it is addressed which are to
         be redeemed, the Redemption Price, the date specified for redemption
         and the place or places at which holders of Series 2 Shares may present
         and surrender such shares for redemption.

4.3.2    On the date so specified for redemption, the Corporation shall pay or
         cause to be paid to or to the order of the Series 2 Holders to be
         redeemed the Redemption Price of such shares on presentation and
         surrender of the certificate or certificates representing the Series 2
         Shares called for redemption at the registered office of the
         Corporation or any other place or places specified in the notice of
         redemption. Payment in respect of Series 2 Shares being redeemed


29

9

         shall be made by check payable to the holder thereof in lawful money of
         the United States at par at any branch in the United States of the
         Corporation's bankers for the time being.

4.3.3    From and after the date specified for redemption in any such notice of
         redemption, the Series 2 Shares called for redemption shall cease to be
         entitled to dividends or any other participation in the assets of the
         Corporation and the holders thereof shall not be entitled to exercise
         any of their other rights as shareholders in respect thereof unless
         payment of the Redemption Price shall not be made upon presentation and
         surrender of the certificates in accordance with the foregoing
         provisions, in which case the rights of the holders shall remain
         unaffected.

4.3.4    The Corporation shall have the right at any time on or after the
         mailing or delivery of notice of its intention to redeem Series 2
         Shares to deposit the Redemption Price of the Series 2 Shares so called
         for redemption, or of such of the Series 2 Shares which are represented
         by certificates which have not at the date of such deposit been
         surrendered by the holders thereof in connection with such redemption,
         to a special account in any specified United States bank named in such
         notice of redemption or in a subsequent notice to the registered
         holders of the shares in respect of which the deposit is made, to be
         paid without interest to or to the order of the respective Series 2
         Holders whose shares have been called for redemption, upon presentation
         and surrender to such bank of the certificates representing such
         shares. Upon such deposit being made, the Series 2 Shares in respect of
         which such deposit shall have been made shall be deemed to have been
         redeemed and the rights of the holders thereof after such shall be
         limited to receiving their proportion (less any tax required to be
         deducted or withheld therefrom) of the amount so deposited without
         interest, upon presentation and surrender of the certificate or
         certificates representing the Series 2 Shares being redeemed. Any
         interest allowed on any such deposit shall belong to the Corporation.

4.3.5    Redemption moneys that are represented by a check which has not been
         presented to the Corporation's bankers for payment or that otherwise
         remain unclaimed (including moneys held on deposit in a special account
         as provided for above) for a period of 5 years from the date specified
         for redemption shall be forfeited to the Corporation.

5.       RESTRICTIONS ON DIVIDENDS, RETIREMENT AND ISSUANCE OF SHARES While any
         Series 2 Shares are outstanding, the Corporation shall not, without the
         approval of the holders of Series 2 Shares given as hereinafter
         specified:

(a)      declare, set aside for payment or pay any dividends on or make
         distributions on or in respect of any Junior Shares (other than
         dividends consisting of Junior Shares); or

(b)      call for redemption, redeem, purchase, retire or acquire for value or
         distribute in respect of any Junior Shares (except to the extent and
         out of net cash proceeds received by the Corporation from a
         substantially concurrent issue of Junior Shares); or


30

10

(c) call for redemption, redeem, purchase or otherwise retire or acquire for value less than all of the Series 2 Shares outstanding; unless, in each such case, all dividends then payable on the Series 2 Shares then outstanding accrued up to and including the dividends payable on the immediately preceding respective date or dates for the payment of dividends thereon shall have been declared and paid or set apart for payment or unless such action has been approved by the Series 2 Holders.

6. LIQUIDATION, DISSOLUTION OR WINDING-UP

In the event of any Liquidation Distribution, each Series 2 Holder shall be entitled to receive before any amount shall be paid by the Corporation or any assets of the Corporation shall be distributed to registered holders of shares ranking as to capital junior to the Series 2 Shares in connection with the Liquidation Distribution, an amount equal to the stated capital per share of all Series 2 Shares held by such holder, together with an amount equal to all accrued but unpaid cumulative dividends thereon. After payment to the Series 2 Holders of the amount so payable to them, they shall not be entitled to share in any further distribution of assets of the Corporation.

7. VOTING RIGHTS

Except as otherwise required by law, the holders of the Series 2 Shares shall not be entitled, as such, to receive notice of or attend or vote at any meeting of shareholders of the Corporation other than a meeting of Series 2 Holders.

8. AMENDMENTS TO SERIES 2 PROVISIONS

These Series 2 Provisions may be repealed, altered, modified, amended or varied only with the prior approval of the holders of the Series 2 Shares given in the manner provided in Section 9 hereof in addition to any other approval required by any statutory provision of like or similar effect applicable to the Corporation, from time to time in force.

9. CONSENTS AND APPROVALS

9.1 The approval of the Series 2 Holders with respect to any and all matters may be given by one or more consents in writing signed by the holders of at least 2/3 of the issued and outstanding Series 2 Shares or by a resolution passed by at least 2/3 of the votes cast at a meeting of the Series 2 Holders duly called for that purpose and held upon at least 10 days' notice, at which the holders of at least 1/3 of the outstanding Series 2 Shares are present or represented by proxy. If at any such meeting the holders of 1/3 of the outstanding Series 2 Shares are not present or represented by proxy within one-half hour after the time appointed for such meeting, then the meeting may be adjourned to such date being not less than 7 days later and to such time and place as may be appointed by the chairman of the meeting.


31

11

9.2 The formalities to be observed with respect to the giving of notice of any such meeting and the conduct thereof shall be those from time to time prescribed by the by-laws of the Corporation with respect to meetings of shareholders.
9.3 On every vote taken at every such meeting or adjourned meeting every Series 2 Holder shall be entitled to one vote in respect of each Series 2 Share of which he is the registered holder.

10. NOTICES

10.1 Any notice required or permitted to be given to any Series 2 Holder shall be sent by first class mail, postage prepaid, or delivered to such holder at his address as it appears on the records of the Corporation or, in the event of the address of any such shareholder not so appearing, to the last known address of such shareholder. The accidental failure to give notice to one or more of such shareholders shall not affect the validity of any action requiring the giving of notice by the Corporation. Any notice given as aforesaid shall be deemed to be given on the date upon which it is mailed or delivered.


32

CERTIFICATE OF DESIGNATIONS
ICHOR CORPORATION

ICHOR Corporation, a Delaware corporation (the "Corporation"), desires to designate the rights and preferences of a series of preferred stock (the "Special Voting Preferred Stock") in accordance with the Corporation's Certificate of Incorporation and Section 151 of the Delaware General Corporation Law. Jin-Soo Choi, the President and a Director of the Corporation, hereby certifies the following:

1. This Certificate is the act and deed of Jin-Soo Choi, the President and a Director of the Corporation. The facts stated in this Certificate are true.

2. The resolutions attached as Exhibit A were duly adopted by the Board of Directors of the Corporation effective March 19, 2001.

3. The number of shares of Special Voting Preferred Stock to which the resolutions at Exhibit A apply is one (1) share.

DATED March 19, 2001.

/s/ Jin-Soo Choi
-------------------------
Jin-Soo Choi
President and Director


33

EXHIBIT A

DIRECTORS' RESOLUTIONS

BE IT RESOLVED THAT:

1. A series of Preferred Stock be and is hereby designated as "Special Voting Preferred Stock" (the "Special Voting Preferred Stock").
2. The number of Special Voting Preferred Stock in the capital of the Corporation be and is hereby fixed at one (1).

3. The Special Voting Preferred Stock shall have attached thereto the special rights and restrictions, as a series, in substantially the form set out in Schedule "A" hereto, with such changes, additions and alterations thereto as any one director or officer of the Corporation may deem necessary or desirable, and that the constating documents of the Corporation be amended as necessary to incorporate same.

4. Any one director or officer of the Corporation be and is hereby authorized to execute and deliver the Certificate of Designations relating to the Special Voting Preferred Stock for and on behalf of the Corporation.


34

SCHEDULE "A"

A series of Preferred Stock, designated Special Voting Preferred Stock (the "Special Voting Preferred Share") shall have attached thereto, in addition to the rights, privileges, restrictions, conditions and limitations attaching to the Preferred Stock as a class, the following rights, privileges, restrictions and conditions:

1. NUMBER OF SHARES. There shall be one Special Voting Preferred Share.
2. DIVIDENDS OR DISTRIBUTIONS. Neither the holder nor, if different, the owner of the Special Voting Preferred Share shall be entitled to receive dividends or distributions in its capacity as holder or owner thereof.

3. VOTING RIGHTS. Except as provided in section 4 below, the holder of the Special Voting Preferred Share shall have the following voting rights:

(a) The holder of the Special Voting Preferred Share shall be entitled to vote on each matter on which holders of the shares (the "Common Shares") of common stock of ICHOR Corporation (the "Corporation"), $0.01 par value per share or stockholders generally are entitled to vote, and the holder of the Special Voting Preferred Share shall be entitled to cast on each such matter a number of votes equal to the number of exchangeable preferential non voting shares of class B of 6543 Luxembourg S.A. (the "Exchangeable Preferred Shares") then outstanding:

(i) that are not owned by the Corporation or its affiliates; and

(ii) as to which the holder of the Special Voting Preferred Share has duly and timely received voting instructions from the holders of such Exchangeable Preferred Shares in accordance with the terms of such Exchangeable Preferred Shares or any agreement governing the provision of voting instructions to the holder of the Special Voting Preferred Share, multiplied by 1,066.44, subject to adjustment by as determined by the board of directors of LuxCo as a result of

(iii) the subdivision, redivision or change of the then outstanding Common Shares into a greater number of Common Shares;

(iv) the reduction, combination or change of the then outstanding Common Shares into a lesser number of Common Shares; or

(v) the reclassification or other change of the Common Shares or the effectuation of an amalgamation, merger, reorganization or other transaction affecting the Common Shares; and


35

(b) Except as otherwise provided herein or by applicable law, the holder of the Special Voting Preferred Share and the holders of Common Shares shall vote together as one class for the election of directors of the Corporation and on all other matters submitted to a vote of stockholders of the Corporation.

4. LIQUIDATION RIGHTS. In the event of voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holder of the Special Voting Preferred Share shall be entitled to receive out of the assets of the Corporation available for distribution to the stockholders, an amount equal to $1.00 before any distribution is made on the Common Shares or any other stock ranking junior to the Special Voting Preferred Share as to distribution of assets upon voluntary or involuntary liquidation. After payment of the full amount of the liquidation preference of the Special Voting Preferred Share, the holder of the Special Voting Preferred Share shall not be entitled to any further participation in any distribution of assets of the Corporation.

For the purposes of this section 4, neither the sale, conveyance, exchange or transfer (for cash, shares of stock, securities or other consideration) of all or substantially all of the property or assets of the Corporation nor the consolidation or merger of the Corporation with or into one or more other entities shall be deemed to be a voluntary or involuntary liquidation.

5. NO REDEMPTION; NO SINKING FUND. The Special Voting Preferred Share shall not be subject to redemption by the Corporation or at the option of its holder, except that at such time as no Exchangeable Preferred Shares (other than Exchangeable Preferred Shares owned by the Corporation or its affiliates) shall be outstanding, the Special Voting Preferred Share shall automatically be redeemed and cancelled, with an amount of $1.00 due and payable upon such redemption. The Special Voting Preferred Share shall not be subject to or entitled to the operation of a retirement or sinking fund.

6. RANKING. The Special Voting Preferred Share shall rank senior to all series of Common Shares of the Corporation and junior to all series of Preferred Stock of the Corporation.

7. RESTRICTIONS. During the term of the Voting Agreement, no term of the Special Voting Preferred Share shall be amended, except upon approval of the holder of the Special Voting Preferred Share.


36

CERTIFICATE OF AMENDMENT
OF CERTIFICATE OF INCORPORATION
OF ICHOR CORPORATION,
A DELAWARE CORPORATION

ICHOR CORPORATION (the "Corporation"), a corporation organized and existing under the General Corporation Law of the State of Delaware (the "General Corporation Law")

DOES HEREBY CERTIFY:

FIRST: That the name of the Corporation is ICHOR CORPORATION, and that the Corporation was incorporated pursuant to the General Corporation Law on September 16, 1996.

SECOND: That on January 19, 2001, the Board of Directors duly adopted resolutions proposing to amend the Certificate of Incorporation of the Corporation and, by written consent in accordance with Section 228 of the General Corporation Law, stockholders of the Corporation holding the requisite number of shares of the Corporation consented to the resolutions setting forth the proposed amendment, which resolutions are as follows:

RESOLVED THAT paragraph 4 of the Certificate of Incorporation of the Corporation be, and is hereby, amended to read as follows:

"4. The total number of shares of all classes of stock which the Corporation shall have authority to issue is Eighty-Five Million (85,000,000) shares, of which Five Million (5,000,000) shares shall be preferred stock, $.0l par value, and Eighty Million (80,000,000) shares shall be common stock, $.01 par value. The preferred stock of the Corporation may be issued from time to time in one or more series. The Board of Directors is expressly authorized, in a resolution or resolutions providing for the issue of such preferred stock, to fix, state and express the powers, rights, designations, preferences, qualifications, limitations and restrictions thereof and to fix the number of shares of such series. Except as otherwise provided by law, the shares of stock of the Corporation, regardless of class, may be issued by the Corporation from time to time in such amounts, for such consideration and for such corporate purposes as the Corporation's Board of Directors may from time to time determine."

THIRD: That the said amendment was duly adopted on May 21, 2001 in accordance with the provisions of Section 242 of the General Corporation Law.

IN WITNESS WHEREOF, this Certificate of Amendment of Certificate of Incorporation has been signed by the President of the Corporation as of May 21, 2001.

By:      /s/ Pierre-Francois Serres
         -----------------------------
         Pierre-Francois Serres, President


37

CERTIFICATE OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION

*****

ICHOR CORPORATION, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:

FIRST: That the Board of Directors of said corporation, by unanimous written consent of its members, filed with the minutes of the board adopted a resolution proposing and declaring advisable the following amendment to the Certificate of Incorporation of said corporation:

RESOLVED, that Article FIRST of the Certificate of Incorporation of ICHOR CORPORATION be amended to read as follows:

FIRST: The name of the corporation is MYMETICS CORPORATION.

SECOND: That in lieu of a meeting and vote of stockholders, the stockholders have given written consent to said amendment in accordance with the provisions of section 228 of the General Corporation Law of the State of Delaware and written notice of the adoption of the amendment has been given as provided in Section 228 of the General Corporation Law of the State of Delaware to every stockholder entitled to such notice.

THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of sections 242 and 228 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, said ICHOR CORPORATION has caused this certificate to be signed by its Secretary this 23rd day of July, 2001.

ICHOR CORPORATION

By       /s/ John M. Musacchio
       ----------------------------
Title:   Secretary


38

CERTIFICATE OF CORRECTION OF
CERTIFICATE OF AMENDMENT
OF
MYMETICS CORPORATION

It is hereby certified that:

1. The name of the corporation (hereinafter called the "corporation") is Mymetics Corporation.

2. The Certificate of Amendment of the corporation, which was filed by the Secretary of State of Delaware on July 23, 2001, is hereby corrected.

3. The inaccuracy to be corrected in said instrument is as follows:

Articles SECOND and THIRD incorrectly indicated that the stockholders gave written consent approval to said amendment in accordance with Section 228 of the General Corporation Law of the State of Delaware.

4. The portion of the instrument in corrected form is as follows:

SECOND: That thereafter, pursuant to resolution of its Board of Directors, the annual meeting of the stockholders of said corporation was duly called and held, upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the amendment.

THIRD: That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

Signed on July 25, 2001                       /s/ John M. Musacchio
                                              -----------------------------
                                              John M. Musacchio, Secretary


39
CERTIFICATE OF RENEWAL AND REVIVAL OF

CERTIFICATE OF INCORPORATION
OF

It is hereby certified that:

1. The name of the corporation (hereinafter called the "corporation") is MYMETICS CORPORATION.

2. The corporation was organized under the provisions of the General Corporation Law of the State of Delaware. The date of filing of its original certificate of incorporation with the Secretary of State of the State of Delaware is September 16, 1996.

3. The address, including the street, city, and county, of the registered office of the corporation in the State of Delaware and the name of the registered agent at such address are as follows: The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801.

4. The corporation hereby procures a renewal and revival of its certificate of incorporation, which became inoperative by law on March 1, 2002, for failure to file annual reports and non-payment of taxes payable to the State of Delaware.

5. The certificate of incorporation of the corporation, which provides for and will continue to provide for, perpetual duration, shall, upon the filing of this Certificate of Renewal and Revival of the Certificate of Incorporation in the Department of State of the State of Delaware, be renewed and revived and shall become fully operative on February 28, 2002.

6. This Certificate of Renewal and Revival of the Certificate of Incorporation is filed by authority of the duly elected directors as prescribed by Section 312 of the General Corporation Law of the State of Delaware.

Signed on May 10, 2002

         /s/ John Musacchio
----------------------------------------
         John Musacchio
         CFO/COO/Secretary


EXHIBIT 10(ii)

EMPLOYMENT AGREEMENT

This Agreement is entered into this 18th day of March, 2002 by and between MYMETICS CORPORATION, a Delaware corporation (hereinafter referred to as the "Company"), and Dr. Joseph D. Mosca (hereinafter referred to as "Executive") under the following terms and conditions:

RECITALS:

WHEREAS, the Company and Executive desire to set forth the terms and conditions on which (i) the Company shall employ Executive, (ii) Executive shall render services to the Company, and (iii) the Company shall compensate Executive for such services; and

WHEREAS, in connection with the employment of Executive by the Company, the Company desires to restrict Executive's rights to compete with the business of the Company;

NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter set forth and intending to be legally bound hereby, the parties hereto agree as follows:

AGREEMENT

1. EMPLOYMENT.

The Company hereby employs Executive and Executive hereby accepts employment with the Company upon the terms and conditions hereinafter set forth.

2. TERM.

2.1 The initial term of this Agreement (the "Initial Term") shall be for a one (1) year period commencing on the Effective Date (as defined in Subsection 2.3 below) of this Agreement, subject, however, to termination as provided herein in Section 6 below.

2.2 Each year, prior to the anniversary date, the Company and Executive shall meet to determine any additional compensation, if any, for the remaining contract term.

2.3 The effective date of this Agreement shall be
[__________], 2002 (the "Effective Date").


3. COMPENSATION.

3.1 For all services rendered by Executive under this Agreement, the Company shall pay or cause one or more of its subsidiaries to pay Executive during the term hereof a salary at the rate of One Hundred Twenty Five Thousand Dollars ($125,000) per year. The Company shall pay such compensation to Executive monthly in accordance with its standard practice for payment of compensation to its employees.

3.2 Executive shall be entitled to periodic cash bonuses in addition to stock bonuses in accordance with the Company's stock option and incentive plans now in effect or hereafter adopted, any other incentive bonus plans or other forms of compensation, at the discretion of the Company's Board of Directors, dependent upon Employee's performance.

3.3 Executive shall be entitled to normal benefits for all Company employees, plus additional benefits which may be added as the benefits plan is developed.

3.4 All compensation shall be subject to customary withholding tax and other employment taxes as are required with respect to compensation paid by a corporation to an employee.

4. DUTIES AND RESPONSIBILITIES.

4.1 Executive shall, during the Term of this Agreement unless otherwise agreed by management, devote his full attention and expend his best efforts, energies, and skills on a full-time basis, to the business of the Company and any corporation controlled by the Company (each, a "Subsidiary"). The Company acknowledges that Executive may from time to time be engaged in other business activities separate from and outside the scope of the business of the Company. The Company agrees that the devotion of reasonable amounts of time to such other business activities will not violate the terms of this Agreement on the conditions that (i) such activities are not corporate opportunities of the Company; and (ii) such activities do not interfere with the performance of Executive's duties hereunder. For purposes of this Agreement, the term the "Company" shall mean the Company and all Subsidiaries.

4.2 During the Term of this Agreement, Executive shall serve as the Vice-President of Development of the Company or in such other capacities as determined by the Board of Directors of the Company. In the performance of all of his responsibilities hereunder, Executive shall be subject to all of the Company's policies, rules, and regulations applicable to its executive of comparable status and shall report directly to, and shall be subject to, the direction and control of the Board of Directors and the President of the Company and shall perform such duties as shall be assigned to him by the Board of Directors and the President of the Company. In performing such


duties, Executive will be subject to and abide by, and will use his best efforts to cause other employees of the Company to be subject to and abide by, all policies and procedures developed by the Board of Directors and the President of the Company.

4.3 To induce the Company to enter into this Agreement, Executive represents and warrants to the Company that (i) Executive is not a party or subject to any employment agreement or arrangement with other person, firm, company, corporation or other business entity, (ii) Executive is subject to no restraint, limitation or restriction by virtue of any law or rule of law or otherwise which would impair Executive's right or ability (a) to enter the employ of the Company, or (b) to perform fully his duties and obligations pursuant to this Agreement.

5. RESTRICTIVE COVENANTS.

5.1 Executive acknowledges that (i) he has a major responsibility for the operation, administration, development and growth of the Company's business, (ii) the Company's business has become international in scope, (iii) his work for the Company has brought him and will continue to bring him into close contact with confidential information of the Company and its customers, and (iv) the agreements and covenants contained in this Subsection 5.1 are essential to protect the business interests of the Company and that the Company will not enter into this Agreement but for such agreements and covenants. Accordingly, Executive covenants and agrees as follows:

5.1.1 Except as otherwise provided for in this Agreement, during the Term of this Agreement and for a period of two years thereafter Executive shall not, directly or indirectly, compete with respect to any services or products of the Company which are either offered or are being developed by the Company as of the date of termination; or, without limiting the generality of the foregoing, by or become, or agree to be or become, interested in or associated with, in any capacity (whether as a partner, shareholder, owner, officer, director, Executive, principal, agent, creditor, trustee, consultant, co-venturer or otherwise) any individual, corporation, firm, association, partnership, joint venture or other business entity, which competes with respect to any services or products of the Company which are either offered or are being developed by the Company as of the date of termination; provided, however, that Executive may own, solely as an investment, not more than one percent (1%) of any class of securities of any publicly held corporation in competition with the Company whose securities are traded on any securities exchange.

5.1.2 During the Term of this Agreement and, for a period of two years thereafter (the "Termination Period"), Executive shall not, directly or indirectly, (i) induce or attempt to influence any employee of the Company to leave its employ, (ii)


aid or agree to aid any competitor, customer or supplier of the Company in any attempt to hire any person who shall have been employed by the Company within the one (1) year period preceding such requested aid, (iii) induce or attempt to influence any person or business entity who was a customer or supplier of the Company during any portion of said period to transact business with a competitor of the Company in Company's business, or (iv) induce or attempt to influence any of the research partners and contract researchers of the Company, which had a contractual relationship with the Company during the term of this Agreement, to terminate or otherwise adversely affect their relationship with the Company or any affiliate of the Company.

5.1.3 During the Term of this Agreement, the Termination Period and any time thereafter, Executive shall not disclose to anyone any information about the confidential or proprietary affairs of the Company, including, without limitation, trade secrets, trade "know-how", inventions, customer lists, business plans, operational methods, pricing policies, marketing plans, sales plans, identity of suppliers or customers, sales, profits or other financial information, which is confidential to the Company or is not generally known in the relevant trade, nor shall Executive make use of any such information for his own benefit.

5.2 If Executive breaches Subsection 5.1 (the "Restrictive Covenants"), the Company shall have the following rights and remedies, each of which shall be enforceable, and each of which is in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity.

5.2.1 Executive acknowledges and agrees that in the event of a violation or threatened violation of any of the provisions of Subsection 5.1.1, the Company shall have no adequate remedy at law and shall therefore be entitled to enforce each such provision by temporary or permanent injunctive or mandatory relief obtained in any court of competent jurisdiction without the necessity or proving damages, posting any bond or other security, and without prejudice to any other rights and remedies which may be available at law or in equity.

5.3 If any of the Restrictive Covenants, or any part thereof, is held to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect, without regard to the invalid or unenforceable portions. Without limiting the generality of the foregoing, if any of the Restrictive Covenants, or any part thereof, is held to be unenforceable because of the duration of such provision or the area covered thereby, the parties hereto agree that the court making such determination shall have the power to reduce the duration and/or area of such provision and, in its reduced form, such provision shall then be enforceable.


5.4 The parties hereto intend to and hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such Restrictive Covenants. In the event that the courts of any one or more of such jurisdictions shall hold such Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the parties hereto that such determination not bar or in any way affect the Company's right of the relief provided above in the courts of any other jurisdictions within the geographical scope of such Restrictive Covenants, as to breaches of such covenants in such other respective jurisdictions, the above covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.

6. TERMINATION.

6.1 Following the Initial Term, this Agreement shall automatically be renewed for additional one-year terms on the anniversary date of this Agreement (each a "Renewal Term" and, together with each Initial Term, the "Term"), unless the Company or the Executive elects to terminate the Agreement by giving 60 days prior written notice. At any time during the Initial Term or any Renewal Term, either party may terminate this Agreement, for any reason or no reason at all, upon 60 days prior written notice to the other party; provided, that if the Company terminates the Executive during the Initial Term for reasons other than for "Cause" (defined below), compensation as defined in Sections 3.1 (base salary) above, shall continue for the remainder of the Initial Term or six months, whichever is greater. If the Company terminates the Executive during any Renewal Term for reasons other than for "Cause", compensation as defined in Sections 3.1 (base salary) above, shall continue for a period of 12 months from the effective date of such termination.

6.2 The Company also may terminate Executive's employment under this Agreement effective immediately at any time for Cause. "Cause" shall exist for such termination if Executive (i) is adjudicated guilty of illegal activities involving moral turpitude by a court of competent jurisdiction, (ii) commits any act of fraud or intentional misrepresentation that may harm the Company, (iii) has engaged in serious misconduct, which conduct has, or would, if generally known, materially adversely affect the good will or reputation of the Company, (iv) is in material breach under this Agreement, or (v) Executive habitually fails to perform the duties and responsibilities of his employment as set forth in Section 4 of this Agreement or as may be assigned or delegated to him from time to time by the Company, the Board, or the Executive Committee of the Board.

6.3 If the Company terminates Executive's employment under this Agreement pursuant to the provisions of Subsections 6.2, Executive shall not be entitled to receive any severance pay.

6.4 If Executive's employment with the Company is terminated as the result of Executive's purely voluntary resignation, Executive shall not be entitled to compensation after the effective date of such resignation.


7. EXPENSES.

7.1 Executive shall be entitled to reimbursement of all reasonable expenses actually incurred in the course of his employment. Executive shall submit to the Company a standardized expense report form, provided by the Company, and shall attach thereto receipts for all expenditures. Expenses shall include business travel.

7.2 The Company shall reimburse Executive within thirty (30) days after submission by Executive of his expense report in correct and appropriate form.

8. THE COMPANY'S AUTHORITY.

Executive agrees to observe and comply with the reasonable rules and regulations of the Company as adopted by the Company's Board of Directors, either orally or in writing, respecting performances of his duties and to carry out and perform orders, directions, and policies stated by the Board of Directors, to him from time to time, either orally or in writing.

9. PAID VACATION; SICK LEAVE; INSURANCE.

9.1 Executive shall be entitled to a paid vacation each year equal to not less than four (4) weeks per year in addition to the paid holidays on which the Company's offices are closed pursuant to Company policy relating to paid holidays.

9.2 Executive shall be entitled to reasonable periods of paid sick leave during the Term of the Agreement in accordance with the Company's policy regarding such sick leave.

9.3 The Company shall provide Executive, at the Company's expense, participation in group medical, accident, disability and health insurance, and life insurance plans of the Company as may be provided by the Company from time to time to Company executives of comparable status, subject to, and to the extent that, Executive is eligible under such benefit plans in accordance with their respective terms.


10. LEGAL DEFENSE; AND INDEMNIFICATION.

The Company acknowledges that the medical/pharmaceutical industry is a litigious industry whereby many regulatory fines, penalties and third-party suits are directed at the individuals involved in ownership and operations. The Company agrees to pay all legal fees, judgments, awards, bonds, fines, penalties and costs related to the defense and outcome whereby Executive was acting in his corporate capacity. The Company acknowledges that from time to time the Executive becomes contingently liable for obligations of the Company. The Company will make whole the Executive in case such contingent obligations becomes direct. Also, in the event that Executive leaves the employ of the Company for any reason, the Company will use its best efforts to remove the Executive from such liabilities, whether contingent or direct.

11. MISCELLANEOUS.

11.1 The Company may, from time to time, apply for and take out, in its own name and at its own expense, life, health, accident, disability or other insurance upon Executive in any sum or sums that it may deem necessary to protect its interests, and Executive agrees to aid and cooperate in all reasonable respects with the Company in procuring any and all such insurance, including without limitation, submitting to the usual and customary medical examinations, and by filling out, executing and delivering such applications and other instruments in writing as may be reasonably required by an insurance company or companies to which an application or applications for such insurance may be made by or for the Company.

11.2 This Agreement is a personal contract, and the rights and interests of Executive hereunder may not be sold, transferred, assigned, pledged or hypothecated except as otherwise expressly permitted by the provisions of this Agreement. Executive shall not under any circumstances have any option or right to require payment hereunder otherwise than in accordance with the terms hereof. Except as otherwise expressly provided herein, Executive shall not have any power of anticipation, alienation or assignment of payments contemplated hereunder, and all rights and benefits of Executive shall be for the sole personal benefit of Executive, and no other person shall acquire any right, title or interest hereunder by reason of any sale, assignment, transfer, claim or judgment or bankruptcy proceedings against Executive; provided, however, that in the event of Executive's death, Executive's estate, legal representative or beneficiaries (as the case may be) shall have the right to receive all of the benefit that accrued to Executive pursuant to, and in accordance with, the terms of this Agreement.

11.3 The Company shall have the right to assign this Agreement to any successor of substantially all of its business or assets, and any such successor and Executive shall be bound by all of the provisions hereof.


12. NOTICES.

All notices, requests, demands and other communications provided for by this Agreement shall be in writing and (unless otherwise specifically provided herein) shall be deemed to have been given three (3) days after having been mailed in any general or branch United States Post office, enclosed in a registered or certified postpaid envelope, addressed to the parties stated below or to such changed address as such party may have fixed by notice:

TO THE COMPANY: Mymetics Corporation At the then current office address for the Secretary or Acting Secretary

COPY TO: James D. Chiafullo, Esq.


Cohen & Grigsby, P.C.
11 Stanwix Street, 15th Floor
Pittsburgh, PA 15222

EXECUTIVE: Dr. Joseph D. Mosca
4201 Blue Barrow Ride
Ellicott City, MD 21042

13. ENTIRE AGREEMENT.

This Agreement supersedes any and all Agreements, whether oral or written, between the parties hereto, with respect to the employment of Executive by the Company and contains all of the covenants and Agreements between the parties with respect to the rendering of such services in any manner whatsoever. Each party to this Agreement acknowledges that no representations, inducements, promises or agreements, orally or otherwise, have been made by any party, or anyone acting on behalf of any party, which are not embodied herein, and that no other agreement, statement or promise with respect to such employment not contained in this Agreement shall be valid or binding. Any modification of this Agreement will be effective only if it is writing and signed by the parties hereto.

14. PARTIAL INVALIDITY.

If any provision in this Agreement is held by a court of competent jurisdiction to be invalid, void, or unenforceable, the remaining provisions shall nevertheless continue in full force and effect without being impaired or invalidated in any way.


15. ATTORNEYS FEES.

Except with respect to paragraphs 5.3 and 5.4 which issues are reserved for the court, any dispute regarding the negotiations leading up to the execution of this Release and/or the interpretation or application of this Agreement or the alleged breach hereof, or any act which allegedly has, or would, violate any provision of this Agreement must be submitted to arbitration before a neutral arbitrator. The arbitration shall be conducted in accordance with the rules of American Arbitration Association. A written demand for arbitration pursuant to Section 638 of the Code of Civil Procedure must be made within sixty (60) days of the alleged breach. The results of arbitration will be the exclusive, final and binding remedy for such claim or dispute.

16. GOVERNING LAW.

This Agreement will be governed by and construed in accordance with the laws of the State of Delaware.

17. BINDING NATURE.

This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective representatives, heirs, successors and assigns.

18. WAIVER.

No waiver of any of the provisions of this Agreement shall be deemed, or shall constitute a waiver of any other provision, whether or not similar, nor shall any waiver constitute a continuing waiver. No waiver shall be binding unless executed in writing by the party making the waiver.

19. CORPORATE APPROVALS.

The Company represents and warrants that the execution of this Agreement by its corporate officer named below has been duly authorized by the Board of Directors of the Company, is not in conflict with any Bylaw or other agreement and will be a binding obligation of the Company, enforceable in accordance with its terms.


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date above written.

MYMETICS CORPORATION

By:  /s/ Dr. Peter P. McCann
     ------------------------------------------
     Dr. Peter P. McCann, President and CEO

EXECUTIVE:

/s/ Dr. Joseph D. Mosca
------------------------------------------
Dr. Joseph D. Mosca